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and §Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IndianaABSTRACT A combination of the extended multiscale model, new image processing algorithms, and biological experiments is
used for studying the role of Factor VII (FVII) in venous thrombus formation. A detailed submodel of the tissue factor pathway of
blood coagulation is introduced within the framework of the multiscale model to provide a detailed description of coagulation
cascade. Surface reactions of the extrinsic coagulation pathway on membranes of platelets are studied under different ﬂow
conditions. It is shown that low levels of FVII in blood result in a signiﬁcant delay in thrombin production, demonstrating that
FVII plays an active role in promoting thrombus development at an early stage.INTRODUCTIONTo prevent the loss of blood after a break in blood vessels,
components in blood and the vessel wall interact rapidly to
form a thrombus, or clot, to limit hemorrhage. This hemostatic
response is rapid to limit bleeding, and is also regulated to
prevent excessive clotting that can limit blood flow. Throm-
bogenesis involves multiple molecular and cellular compo-
nents in the blood and interactions among multiple processes
ranging from coagulation, and platelet biology, to hemody-
namics. Given the complexity of the thrombus formation
process, computational modeling is becoming a very impor-
tant complementary tool for traditional laboratory studies.
The successful development of a computational predictive
model of thrombogenesis—a model able to integrate
processes occurring at different scales—is still a challenge.
In Xu et al. (1,2) a two-dimensional multiscale model of
the developing thrombus was introduced that included
components for modeling viscous, incompressible blood
plasma; nonactivated and activated platelets; other blood
cells; activating factors; fibrinogen; and the blood vessel
wall. Macroscale dynamics of the blood flow was described
by the continuum Navier-Stokes equations. Microscale inter-
actions among activated platelets, platelets and fibrin(ogen),
and platelets and the vessel wall were described through an
extended stochastic discrete cellular Potts model (CPM).
A coagulation pathway submodel has been recently added
to the model in Xu et al. (3).
In this article, the two-dimensional multiscale model of
thrombus formation is extended by including surface-medi-
ated control of the coagulation pathway resulting in detailed
modeling of the impact of all major coagulation and antico-
agulation factors on thrombin generation. The novelty of the
approach is in representing each platelet as an extendedSubmitted July 31, 2009, and accepted for publication December 28, 2009.
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0006-3495/10/05/1723/10 $2.00object with the boundary changing volume, and modeling
in detail the production of thrombin by each individual
platelet. In addition, the clot is treated as a porous medium.
New image analysis tools introduced in Mu et al. (4,5) are
used to estimate model parameter values (see Supporting
Material for details).
The extended two-dimensional multiscale computational
model was used to simulate thrombus formation in normal
mice and mice with limited levels of factor VII (FVII). Simu-
lation predictions have been compared with experimental
results involving thrombogenesis after laser-induced injury
of venules in wild-type and FVII deficient mice to gain
improved understanding of coagulation factors and the role
of hydrodynamics. It was shown that low level of FVII
significantly delayed the rise in thrombin concentration.
Comparison with experimental data suggests that this delay
affects the final structure of the clot—which has significant
biomedical implications.
This article is organized as follows. Biological and
Modeling Background is provided in the next section. Mate-
rials and Methods describes the experimental materials and
methods used, and Extended Multiscale Model presents the
new extended multiscale model with surface-mediated
control of the blood coagulation cascade. We then provide
our simulation and experimental results. The article ends
with our Conclusions. Image analysis algorithms used in
the article as well as detailed description of the biochemical
reactions submodel equations including protein C pathway
(PC) component and CPM are described in detail in the Sup-
porting Material.BIOLOGICAL AND MODELING BACKGROUND
Given space limitations, the following description of
thrombus generation is simplified. The subject is described
in more detail in several recent reviews (6–9).doi: 10.1016/j.bpj.2009.12.4331
1724 Xu et al.After vascular injury, blood is exposed to prothrombotic
environments that promote rapid thrombus formation.
Thrombus formation is the result of two interrelated
processes—platelet interactions and coagulation pathway
activation. Immediately after vessel damage, platelets adhere
to the site of vessel injury forming a single cell layer by the
binding of platelet receptors gpIb/IX to von Willebrand
factor (vWF) and gpIa/IIa and gpVI to collagen in the suben-
dothelial matrix of the vessel wall (10). Subsequently, plate-
lets adhere to each other and form multicellular aggregates
mediated by the binding of the platelet gpIIb/IIIa receptor
to fibrin(ogen). In addition, platelets undergo activation
involving significant morphological changes, i.e., the expo-
sure of new proteins on the platelet surface and the extracel-
lular release of contents of a- and dense granules found in
resting platelets. Activated platelets also expose negatively
charged phospholipids that promote surface-dependent coag-
ulation reactions. It is generally accepted that the coagulation
cascade is initiated when coagulation factor VII in the blood
is exposed to its cellular receptor, the tissue factor (TF),
which is expressed on endothelial cells in the vessel wall
(11). The TF/VIIa complex catalyzes the conversion of
factor X to Xa directly or via an IXa/VIIIa intermediary
step. Activated factor Xa combines with its protein cofactor,
factor Va, on the surfaces of platelets to form prothrombinase
(FVa/FXa complex), which, in turn, converts prothrombin
(II) to thrombin (IIa) through an intermediate meizothrombin
(mIIa). This intermediate (mIIa) is transient, and is rapidly
converted to IIa in the presence of factor Va and procoagu-
lant lipids. Factor V is activated to its active form Va by
both factor Xa and IIa. Thrombin activates platelets; converts
fibrinogen to fibrin; and activates factors V, VIII, and XI,
which provide a positive feedback loop propagating the
production of thrombin. Thrombin is also a potent activator
of resting platelets and thus mediates recruitment of resting
platelets flowing nearby in the blood. The activated platelets
provide a procoagulant surface that promotes coagulation
enzyme activity. The formation and activity of the VIIIa/
IXa and Va/Xa complexes are dependent on the availability
of phospholipid binding sites. These binding sites are only
present on surfaces of activated platelets.
Several anticoagulant components in blood inhibit
different targets of the coagulation complexes. Tissue factor
pathway inhibitor (TFPI) forms a quaternary complex with
factor Xa, TF, and VIIa, effectively inhibiting TF/VIIa initi-
ation of the coagulation cascade. The procoagulant activities
of thrombin, IXa, and Xa, are inhibited by antithrombin III
(ATIII), whose inhibitory activity is enhanced by binding
glycosamine glycans exposed on the resting endothelium.
Additionally, Protein C (PC) is activated to active Protein
C (APC) by thrombomodulin and thrombin complex to
form a negative feedback loop. The blood flow substantially
affects growth and development of thrombus. Platelet recep-
tors (gpIba) and ligands (vWF) form catch-slip bonds, so
shear has an effect on the strength of adhesive forces teth-Biophysical Journal 98(9) 1723–1732ering platelets to the vessel wall. Gene expression patterns
of endothelial cells cultured under flow or stasis are also
different. Inflammatory markers are expressed by cells
growing under static conditions.
The first systematic model of the coagulation pathway was
introduced in Jones et al. (12) and Lawson et al. (13).
Recently, this model has been extended to include inhibitors
that are recognized as integral parts of the coagulation
system (14). Bungay et al. (15) proposed a comprehensive
model for the dynamics of thrombin formation for vascular
and nonvascular systems that distinguished reactions on
cell membrane and in bulk flow. Both of these models
assume a uniformly mixed, static fluid environment and an
unlimited supply of phospholipid. The role of phospholipid
surfaces in controlling coagulation was not addressed.
McGee and Chou (16) studied initial surface reactions of
the extrinsic coagulation pathway on live cell membranes
under flow conditions. Several other models have been
developed in an attempt to integrate some of the subpro-
cesses involved in thrombus formation. A model described
in Kuharsky and Fogelson (17) includes the transport of
blood flow and a finite number of surface binding sites.
However, the flow transport and reactant diffusion were
incorporated into the model by using empirical parameters.
Newtonian fluid models have been described in Fogelson
(18) and Sorensen et al. (19) in the form of coupled convec-
tion-reaction-diffusion equations. (See (20–22) for other
related articles.)MATERIALS AND METHODS
We have used multiphoton intravital microscopy to monitor thrombus devel-
opment in mouse venules (diameter being ~100 mm). C57Bl/5 mice, 6-8
weeks of age (Harlan, Indianapolis, IN) and low FVII mice (maintained in
the animal facilities at the Indiana University School of Medicine) were
used in accordancewith National Institutes of Health guidelines and approval
of the Institutional Animal Care and Use Committee of the Indiana Uni-
versity School of Medicine. The mesentery vascular bed surrounding the
intestines were surgically externalized from an anesthetized mouse and posi-
tioned under a model No. LSM-510Meta Confocal/Multiphoton microscope
(Carl Zeiss, Oberkochen, Germany) so one could monitor blood flow
through blood vessels.
Mice were injected with labeled dextran (Molecular Probes, Eugene, OR)
to detect plasma (Enzyme Research Labs, South Bend, IN), anti-CD41 anti-
body to monitor platelets (Emfret, Wu¨rzburg, Germany) and labeled fibrin-
ogen (Enzyme Research Labs) that enabled one to monitor the incorporation
of major components into the growing thrombus. After laser-induced injury
to the venule wall, vertical stacks of images of developing thrombi were
collected continuously for 30 min, enabling one to generate three-dimen-
sional reconstructions of the developing thrombus in vivo (see Kamocka
et al. (27) for details). Using the image processing algorithms described in
the Supporting Material, we quantitated the changing composition of
specific domains during thrombus development.EXTENDED MULTISCALE MODEL
The multiscale model introduced in Xu et al. (1,2) is
extended in this article by including a detailed submodel of
surface-mediated control of blood coagulation and by
FIGURE 1 Snapshot of a clot forma-
tion simulation obtained using multi-
scale model. (Black) Cells made of the
fibrin network; these cells are termed
‘‘fibrin cell’’. (Red) Cells that are inac-
tive platelets. (Green) Cells representing
platelets right after activation (<1 min
from exposure to activating thrombin
concentration). (Blue) Cells representing
late-activated platelets that can support
coagulation reactions and bind fibrin
(ogen).
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following components and processes at different scales: plate-
lets and other blood cells; blood plasma; subendothelial cells;
blood vessel wall; injury; platelet-platelet adhesion; activa-
tion; blood plasma flow; an extrinsic coagulation pathway
that takes into account solution phase and membrane-phase
enzymes and zymogens; coagulation inhibitors; and diffusion
of solution-phase reactants. Specific submodels for processes
involving components described above are as follows:
Biochemical reactions submodel
Systems of ordinary differential equations (ODEs) and
partial differential equations (PDEs) are used to describe
the coagulation cascade.
Cell submodel
Discrete stochastic CPM represents different types of cells as
well as describes cell-cell and platelet-injury adhesion,
platelet activation, cell movements, cell state changes and
platelet aggregation.
Flow submodel
Incompressible Navier-Stokes (NS) equations and Darcy’s
law describe dynamics of viscous blood plasma.
Cellular Potts model
The cellular Potts model (CPM) for modeling blood clot
formation consists of a list of generalized cells on a lattice,
a set of chemical diffusants, and local rules describing their
biological and physical behaviors. Interactions of CPM
components are embodied in the effective cell energy,
coupled to auxiliary equations to describe absorption and
secretion of diffusants and extracellular materials, state
changes within cells, and the behavior of extracellular diffu-
sants. Each platelet or other blood cell is represented in the
CPM by a cluster of lattice sites. Distribution of multidimen-
sional indices associated with lattice sites determines current
system configuration. The Metropolis dynamics algorithm,
based on the Monte Carlo Boltzmann acceptance rule, is
used to determine CPM configuration. The effective CPM
energy of the thrombus mixes true energies, such as
platelet-platelet adhesion, and terms that mimic energies,
e.g., the response of a cell to the flow pressure, and areaand shape constraints. Biochemical reactions as well as
chemical production are modeled on the surface of each
cell. (The details can be found in Xu et al. (1,2) and in this
article’s Supporting Material.)
All the different components of the multiscale model,
including the ones modeled by the CPM, are indicated in
Fig. 1. In the simulation, platelets can get activated and
adhere to each other and to the injury site. New inactivated
platelets are introduced in the simulation domain from the
inlet—the left side of a domain at a specified rate, and are
carried by the flow to the right.
Blood ﬂow submodel
The blood clot is treated in this article as a porous medium to
account for the transport property of blood flow. In the case
of vein thrombus formation studied in this article, the Rey-
nolds number of the blood flow is %O(1). Therefore, we
describe the blood flow within the clot by Darcy’s law.
A complete flow submodel consists of the combination of
the NS equations (Eq. 1) and Darcy’s law (Eq. 2). Namely,
we solve NS equations outside the clot, use Darcy’s law
within the clot, and then couple them using the domain
decomposition approach,
vu
vt
þ u  Vu ¼ 1
r
Vp þ nV2u;
V  u ¼ 0; u ¼ k
n
Vp:
(1)
u ¼ k
n
Vp: (2)
where r is the fluid density, u and p are volume-averaged
velocity and pressure, respectively, and n is the shear
viscosity. The permeability k of the blood clot is related to
porosity by the Davies’ equation presented by Dullien
(23). Blomba¨ck et al. (24) correlated this equation with the
data for permeability measurements made on fibrin gels
polymerized under various thrombin concentrations.
Because we model clots largely made of platelets, we use
the Davies’ equation for larger porosity,
k ¼ D
2
fiber
64ð1 eÞ3=21:0 þ 56ð1 eÞ3
;
where e is a porosity.Biophysical Journal 98(9) 1723–1732
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We extend the approach of Hockin et al. (14) by including in
the model both solution-phase and membrane-phase reac-
tions with concentrations of membrane-binding sites being
limited and treated as control variables. In addition, factor
XI is included in the model because it provides a positive
feedback loop for coagulation:
XI þ IIa#XI: IIa/XIa þ IIa;
XIa þ IX#IXa: IX/XIa þ IXa:
The resulting coagulation submodel consists of 22 PDEs and
23 ODEs without considering the Protein C pathway (see
Supporting Material). The discussion of the PC pathway is
given separately, below, in Protein C Pathway Component.
The PDEs describe rates of change of the concentration of
each solution-phase factor or complex; and the ODEs des-
cribe rates of change of the concentration of each mem-
brane-phase factor or complex. The model variables include
the following 22 solution-phase factors and complexes:
VII, VIIa, Xa, II, IIa, X, IX, IXa, VIII, VIIIa, VIIIa1L,
VIIIa2, V, Va, mIIa, TFPI, Xa:TFPI, ATIII, Xa:ATIII,
mIIa:ATIII, IXa:ATIII, and IIa:ATIII,
and membrane-phase factors and complexes:
TF, TF:VIIm, TF:VIIa
m, TF:VIIma:X, TF:VII
m
a:Xa,
TF:VIIma:IX, IXa:VIIIa, IXa:VIIIa:X
m, Xa:Va, Xa:
Va:II
m, TF:VIIma:Xa:TFPI, TF:VII
m
a:ATIII, Xa
m,
IIma, X
m, IXm, IXa
m, IIm, VIIIm, VIIIma, V
m, Vma,
and mIIma.
The membrane-phase reactants are indicated by a superscript
m except for TF, which only occurs on subendothelial cells,
tenase IXa:VIIIa, and prothrombinase Xa:Va.
Submodel assumptions
Platelets in resting state can be activated in our model in
three ways:
Assumption 1. By binding to subendothelial cells.
Assumption 2. By getting in contact with activated plate-
lets.
Assumption 3. By exposure to high concentration of
thrombin (IIa).
Production of chemicals such as ADP secreted by platelets is
not included in the current model. The effect of ADP is
modeled through platelet activation resulting from a contact
with already-activated platelets.
Activated platelets provide membrane-binding sites where
surface-binding zymogens and enzymes react. We assume
that factors X and Xa directly bind to factor VIIa without first
binding to the subendothelium. Following Hockin et al. (14),
activation of factor V is due to IIa. Activation of factor VIII is
assumed to be through IIa as well. We also assume that the
chemical mechanism of factor VIIIa losing activity results
from spontaneous A2 domain dissociation. VIIIa1L andBiophysical Journal 98(9) 1723–1732VIIIa2 are assumed to exist in liquid only, for the simplicity
of computation. (We assume that the existence of VIIIa1L
and VIIIa2 on platelet membrane is transient, and therefore
find it justifiable to include only their liquid phase form
into the model.)
Description of the coagulation submodel
The submodel is described in detail in the Supporting Mate-
rial. Dynamics of plasma-phase thrombin is represented by
the following PDE (Eq. S4.7) in the Supporting Material:
v½IIa
vt
þ u V½IIa ¼ DIIaV2½IIa  kon2 ½IIa

p2  emtot2  zmtot2

þ koff2

IIma
 k41½IIa½ATIII;
where the term k2
on[IIa](p2 – e
mtot
2 – z
mtot
2) is the rate at
which plasma-phase thrombin binds to the surface of an acti-
vated platelet, p2 is the volume concentration of binding sites
for platelet-bound thrombin (IIa), prothrombin (II), and mei-
zothrombin (mIIa) on an activated platelet, and zmtot2 and
emtot2 are the concentrations of platelet-bound prothrombin
(II), and thrombin (IIa), and meizothrombin (mIIa), respec-
tively, on an activated platelet, together with their platelet-
bound complexes. The expression k2
off[IIa
m] is the rate of
dissociation of thrombin from a platelet surface and
k41[IIa][ATIII] is the rate at which plasma-phase thrombin
and plasma-phase anti-thrombin III bind to form IIa/ATIII
complex. The expressions u  V[IIa] and DIIaV2½IIa repre-
sent convection and diffusion of plasma-phase thrombin.
The following system of ODEs (Eq. S4.36) describes
dynamics of platelet-bound thrombin,
d

IIma

dt
¼ kon2 ½IIa

p2  emtot2  zmtot2
 koff2

IIma

þ k16

Xma
½IIm þ k32

mIIma
½Xa : Va;
where k16[Xa
m][IIm] is the rate of conversion of platelet-
bound prothrombin (IIm) to platelet-bound thrombin (IIa
m)
by platelet-bound Xma.
Note that convection and diffusion terms are neglected in
Eqs. S4.1–S4.50 in the Supporting Material. Resulting
system of ODEs called modified Mann’s ODE model, was
used to estimate some parameter values for the multiscale
model.
Estimation of parameter values
Most of the reaction rates were taken from Hockin et al. (14),
where experimentally measured values of rate constants
were used. The on-rates (kon) and off-rates (koff) of binding
reactions were taken from Kuharsky and Fogelson (17). It
is not possible at the moment to measure volume concentra-
tion of membrane binding-sites for all surface-dependent
factors (i.e., p2 in Eq. S4.7). Instead, we converted numbers
of membrane binding-sites on single platelet from Kuharsky
and Fogelson (17) to values of volume concentration
A Multiscale Model of Venous Thrombus 1727obtained by using numerical experiments. (See Results for
details.) The average values of porosity of blood clots were
obtained using image analysis (see Supporting Material for
details).
Protein C pathway component
It is commonly agreed that thrombin and thrombomodulin
(TM) on endothelial cells bind to form TM-IIa complex
(25). Protein C (PC) is activated to APC by TM-IIa to form
a negative feedback loop in which APC inactivates factors
(FV and FVIII) that are essential for continued thrombin
generation. (For further discussion of the APC, see Support-
ing Material.) Although our model is two-dimensional, we
assume an extension of the simulation domain in the lateral
direction perpendicular to the flow to describe the protein C
mechanism. We assume that thrombin (IIa) generated in the
thrombus can diffuse laterally onto the endothelium. APC is
also delivered to the thrombus through the diffusion process.
APC can be carried away by the flow as well. (A similar
approach has been used in Fogelson and Tania (26).)
The dynamics of the concentration of the thrombin over
endothelial IIa
EC is described by Eq. S4.46. Note that:
[TM] is the total concentration of thrombomodulin on
endothelial cells.
Ddiff;IIECa ð½IIa  ½IIECa Þ is the diffusion of IIa onto endothe-
lial surfaces.
ktm
on[IIa
EC]([TM] – [TM:IIa] – [TM:IIa:PC]) is the
binding of IIa to TM.
ktm
off[TM:IIa] represents the dissociation of the TM-IIa
complex.
Production of APC on endothelial cells is modeled by
Eq. S4.49. Produced APC diffuses into the clot and binds
to factor VIIIa
m and Va
m, which is described by Eq. S4.50.
Because we do not have the true third dimension in the
model, the flow velocity over endothelial cells is approxi-
mated by u0, which is the averaged flow velocity in the simu-
lation domain.
Integration of submodels into a multiscale model
We assume that the thrombus is not changing while updating
the blood flow velocity field during one time step. Convec-0 100 200 300 400 500 600
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a btion-reaction-diffusion equations are solved by using an
operator splitting approach, i.e., an intermediate chemical
field is calculated by ignoring reaction terms in the equa-
tions. Then this field is used as initial condition for the
system of ODEs that contain only reaction terms of the orig-
inal equations.
During each numerical step (after retrieving the thrombus-
plasma interface from the CPM grid), the NS equations,
Darcy’s law, and convection-reaction components of
convection-reaction-diffusion equations for the flow and
chemical distributions are solved simultaneously. After the
PDE step described above, the biochemical reaction submo-
del is used, i.e., the reaction parts of convection-reaction-
diffusion equations and ODEs are solved for each activated
platelet to simulate surface-mediated coagulation. The result
in turn is used in the subsequent CPM updates of cell posi-
tions, cell shapes, and types. It is also assumed that, during
the CPM iteration, flow conditions (velocity and pressure)
remain unchanged. After the CPM step is finished, the latest
CPM data (interface geometry and chemical concentrations)
provide updated boundary and initial conditions for the
continuous model. The flow energy term in the CPM Hamil-
tonian is used to describe the impact of the blood flow on the
cells (see Supporting Material for details).RESULTS
Preliminary simulations
We first calibrated the coagulation submodel by simulating
the role of factor XI (see Supporting Material).
Impact of clot porosity on thrombin production
Analysis of experimental three-dimensional images of
a growing clot demonstrated that clot porosity was ~0.22,
0.15, and 0.08 at the initial, intermediate, and late stages of
clot development, respectively. Fig. 2 shows the effect of
porosity on thrombin generation. Fig. 2 a compares thrombin
concentration when porosity ¼ 0.1, and 0.15, respectively,
for flow velocity ¼ 0.05 mm/s. We see similar trend in
thrombin generation regardless of porosity. Fig. 2 b compares
thrombin concentration with porosity ¼ 0.1, and 0.15,
respectively, and flow velocity ¼ 0.5 mm/s. The maximum300 400 500 600
Time (sec)
 
FIGURE 2 Total thrombin genera-
tion with porosity ¼ 0.1 and 0.15. (a)
Flow velocity ¼ 0.05 mm/s; (b) flow
velocity ¼ 0.5 mm/s.
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FIGURE 3 Total thrombin generation in simulations with flow velocity ¼ 0.05 mm/s, 0.5 mm/s, and 1 mm/s, respectively. (a) Total thrombin generation
without inhibitors ATIII and TFPI. (b) Total thrombin generation with inhibitors ATIII and TFPI.
1728 Xu et al.of thrombin concentration is reached when the time is ~250 s
for porosity ¼ 0.1 followed by a slight decrease. Neverthe-
less, both cases show similar thrombin production after
400 s. We therefore conclude that thrombin production is
similar for different porosity values (at least in the later
time) and that using a fixed average porosity value for all
times is justified.
Impact of blood ﬂow on the coagulation
Fig. 3 shows average values of thrombin production within
simulated clots with respect to time. Comparison between
Fig. S2 b in the Supporting Material and Fig. 3 in the article
demonstrates the impact of blood flow as well as coagulation
factor binding site on platelet surface on thrombin produc-
tion and clot formation. Thrombin production displays qual-
itatively different behavior under static (modeled by ODE)
and flow (simulated by the multiscale model) conditions.
Comparison clearly shows that in multiscale model simula-
tions, even with anticoagulants, thrombin concentration
remains almost constant within the clot, whereas in the
ODEs model/or under static condition simulations, thrombin
is deactivated quickly after it reaches the peak value because
of anticoagulants. There are several reasons contributing to
these differences. The PDE submodel takes into account
spatial variation of chemical concentration and blood flow
effect. In addition, the multiscale model takes into account
a finite number of binding sites on platelet surface for factors
V, IX, X, VIII, etc., whereas the ODE model assumes an in-
finite supply of these binding sites. Therefore, in the multi-
scale model, the coagulation reaction on platelet surface is
actually regulated by the available binding sites.
Role of the factor VII
Experimental results
We have compared thrombus development in wild-type and
genetically modified mice expressing very low levels of
coagulation FVII (0.1–1% of wild-type levels) by the tech-
nique developed in Rosen et al. (28). After laser-inducedBiophysical Journal 98(9) 1723–1732injury, the growth characteristics of thrombi in low FVII
and wild-type mice are markedly different. With the injury
parameters used in this study, wild-type thrombi grow
rapidly. The second structure of the series has the largest
volume, indicating the thrombus reaches peak size between
2 and 3 min after injury. After peaking, the volume of the
wild-type thrombus decreases by ~50% and reaches a stable
conformation by the fifth-to-seventh structure (7–9 min after
injury). In contrast, low FVII mice form unstable thrombi.
Platelets accumulate immediately after injury, but the
volumes decreases as platelets detach from the structure.
The volume of the thrombi then slowly increases, reaching
~70% of the volume of a wild-type clot (see Fig. 4). We
hypothesize that this apparently novel experimental observa-
tion is related to the delayed thrombin generation, which is
predicted from our simulations (see Fig. 5 a). However,
the actual biological mechanism leading to this behavior is
not fully understood and is subject to future study.
Simulation results
Using simulations with an estimated 0.1% of normal concen-
tration of FVII, we showed that there was a significant time
delay in thrombin production reaching its peak value. The
total thrombin concentration in the case of 0.1% of normal
concentration of FVII was, after reaching the peak, approx-
imately one-third of the concentration obtained in the case
of the normal levels of the FVII (see Fig. 5 a).
The simulation predicts that thrombin generation is de-
layed, and the thrombin concentration is lower in low FVII
thrombi, compared to wild-type (see Fig. 5 a).
In the experimental system, initially the wild-type
thrombus grows rapidly, reaching peak volume at 2–3 min,
and then decreases in size, reaching a stable volume at
6–9 min (see Fig. 4 b). This phenomenon most probably
results from the decrease in platelet volume that occurs at
the end of the activation process. Although resting platelets
are discoid, initially after activation they become spherical
with irregular protrusion and release contents of a- and dense
granules. With the extension of filipodia attaching to matrix
FIGURE 4 (a) Time sequences of experimental cross-section images taken close to lumen, representing structures 1, 2, 3, 8, and 10 in the image series taken
for each injury. (Top and bottom) Images of thrombi in wild-type and low FVII cases, respectively. Each structure takes ~80 s to acquire. (Green) Voxels made
of fibrinogen only, (red) made of platelets only, and (black) with exclusion of all probes. (b) Diagram demonstrating growth of wild-type and low FVII thrombi
obtained using analysis algorithms of three-dimensional reconstructed experimental images. Average volume of thrombi (vertical remixes) were determined by
the number of voxels in a three-dimensional reconstructed images.
A Multiscale Model of Venous Thrombus 1729components within the thrombus, the platelets then spread
and flatten. These initial increases are followed by decreases
in volume of platelets during activation—which most prob-
ably contributes to the rapid increase and then decrease in
thrombus volume that one sees in the experimental results.
We incorporated initial increase followed by decrease in
volume of platelets in the CPM model by adjusting target0 50 100 150 200 250 300 350
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a bcell volume with time (see Supporting Material). Simulations
demonstrated the clot size reaching peak value at 3 min and
then dropping and stabilizing (see Fig. 5 b), which is consis-
tent with the experimental observations presented in Fig. 4 b.
One feature of the growth pattern of low FVII, which the
simulation does not predict at this time, is the dip in volume
observed in developing low FVII thrombi. As the initial150 200 250 300 350
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FIGURE 5 (a) Total amount of
thrombin generated in simulations with
concentration of FVII ¼ 1.0, 0.1% of
normal concentration. (b) Simulated
wild-type clot size in numbers of pixels
of cells.
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FIGURE 6 The effect of PC on
thrombin generation in simulations with
different flow velocities. (a) Flow velo-
city ¼ 0.05 mm/s; (b) flow velocity ¼
0.5 mm/s.
1730 Xu et al.adhesion of platelets to the injury site is mediated by platelet
attachment to collagen and vWF in the exposed subendothe-
lial matrix, we expect platelets in low FVII and wild-type
mice to initially bind similarly. However, in the experimental
system the number of platelets accumulated in low FVII
mice is less than that of wild-type at the earliest time point,
which indicates some unknown biological mechanisms.
Furthermore, that initial adhesion is transient, as the volume
of the FVII thrombus dips in low FVII thrombi. This exper-
imental result suggests that thrombin generation is necessary
for stable platelet adhesion as well as continued platelet
aggregation. We, therefore, plan to modify the model to
include thrombin-mediated stabilization of the initial
platelet-vessel wall interaction in our future study.
Role of the APC
Fig. 6 shows average values of thrombin production within
simulated clots with respect to time when PC pathway is
included in the coagulation model. Fig. 6 a compares the
thrombin production when the PC pathway is included,
with that of the case without inclusion of PC pathway, for
flow velocity ¼ 0.05 mm/s; and Fig. 6 b compares the
thrombin production when the PC pathway is included,
with that of the case without inclusion of PC pathway, for
flow velocity ¼ 0.5 mm/s. Although for both simulations,
the cases with inclusion of PC pathway show a reduction
in the amount of thrombin production, thrombin production
displays qualitatively similar behavior under different flow
conditions regardless of PC. Moreover, thrombin concentra-
tion is still far above the threshold value (1 nM) to activate
resting platelets. Because we model the early development
stage of clot formation, we conclude that PC is not important
at the early stage.
How might one explain the epidemiological evidence that
low levels of PC are associated with thrombosis (29)?
Conceivably, PC might not play a major role stopping the
growth of a developing thrombus but inhibit the initiation
of coagulation caused by endothelial cell activation or
dysfunction. This might result from PC inhibition of
thrombin generation initiated on endothelium that is acti-
vated by reduced flow, hypoxia, or inflammatory signals.Biophysical Journal 98(9) 1723–1732Additionally, it has recently been appreciated that PC has
antiinflammatory and cytoprotective functions independent
of its inactivation of FVa and FVIIIa, which have led to
the use of APC in the treatment of severe sepsis (30).
However, endothelial activation by inflammatory signals is
not the situation in our experimental and computational
model because we are using a laser-induced injury to induce
an acute endothelial injury that disrupts endothelial cells.CONCLUSIONS
In this article, a two-dimensional multiscale model is
described that includes submodels of extended discrete cell
representation, continuous blood flow, and the surface-medi-
ated coagulation pathway. The results of simulations ob-
tained using this model have been compared with results
from an experimental model of laser-induced vessel injury
in mice. Using intravital multiphoton microscopy, vertical
stacks of images of developing thrombi were generated
and analyzed using novel image processing algorithms.
Because our model is two-dimensional, some three-
dimensional effects, such as turbulent flow, cannot be
described. However, turbulence is not a concern for our
study of venous thrombus development, because the blood
flow is rather slow. Under the assumption of flow being
laminar, our model is capable of simulating a two-dimen-
sional slice from the middle of the clot and capturing impor-
tant characteristics of the clot formation. For instance, in our
previous articles (28,29), we correctly simulated the depen-
dence of clot size on the flow rate. Moreover, the reaction
rates of coagulation pathway, i.e., the physical scales (units)
of clot formation processes such as activation of platelets by
thrombin and the delay time for forming firm bonds between
pairs of platelets, do not depend on the dimension.
Comparing results from the multiscale simulations and
experimental models, we are able to estimate parameter
values used in the simulations and to study roles of coagula-
tion factors quantitatively. Moreover, these comparisons
enable us to validate the multiscale model, and they suggest
the inclusion of new components in the model so that the
roles of hemostatic factors can be analyzed in silico.
A Multiscale Model of Venous Thrombus 1731Additionally, simulations correctly predict the growth char-
acteristics of wild-type thrombi.
Initial simulations examining the role of coagulation FVII
are consistent with the quantitative results generated by the
experimental injury model. The delay in thrombin generation
at very low levels of FVII predicted in the simulations is
consistent with the reduced stability at early times after
injury of thrombi developing in FVII-deficient mice
compared to those in wild-type. After injury, the exposure
of platelets in blood to the damaged vessel wall leads to
platelet adhesion to the injury site. Thus, the initial structures
of thrombi in both wild-type and low FVII mice show signif-
icant platelet accumulation. However, whereas wild-type
thrombi grow rapidly after injury, thrombi in FVII-deficient
mice get smaller, consistent with the multiscale model
prediction that there is a prolonged delay before significant
accumulation of thrombin in low FVII mice. Because
thrombin is a potent platelet activator, the delay in thrombin
generation potentially leads to delayed platelet activation and
reduced adhesiveness and aggregation. Furthermore, delayed
thrombin generation also results in delayed accumulation of
fibrin (which is a provider of structural stability to the
thrombus). Thus, the delayed thrombin accumulation pre-
dicted for low FVII is consistent with the reduced stability
of thrombi in low FVII mice after the initial adhesion of
platelets at the injury site.
In the experimental system, there are greater fluctuations
in the volume of thrombi in the low FVII mice compared
to those in wild-type. This is because the experimental model
incorporates the development of matrix cells composed of
polymerized fibrin. To refine the simulation model to
account for this observation, we are currently working on
modeling the development of matrix cells that are composed
of polymerized fibrin. These fibrin cells will stabilize the clot
structure by inhibiting embolization while interfering with
coagulation reactions on the surface of activated platelets.
Presumably, because there is delayed and reduced thrombin
generation in mice with low FVII levels, we expect to accu-
mulate less fibrin after a longer delay than predicted in
wild-type animals, which would result in delayed and
reduced fibrin generation. This delayed and reduced fibrin
generation will result in compromised structural integrity
as well as reduced interference with platelet-surface-medi-
ated coagulation, leading to cycles of embolization and
thrombus regrowth.
Simulations suggest that appreciable changes in the delay
of thrombin generation are first observed at very low levels
of FVII (0.1–1.0% of wild-type). These predictions are
consistent with observations comparing survival of FVII/
null and FVIItta/ mice. Although FVII/ mice die embry-
onically when sired by mothers with reduced FVII level,
most FVIItta/ mice survive >3 months. This suggests that
FVII levels in FVIItta/ mice, which are <1.0%, are above
a threshold that permits survival. These results are consistent
with the simulation indicating that only when one gets toFVII levels <1% is there a significant difference in the
dynamics of thrombin generation.
We have demonstrated that the multiscale computational
model could provide a valuable tool in the study of throm-
bosis. For instance, although specific thrombotic risk factors
have been identified, the consequences to individuals with
aberrant risk factor levels are often variable, and probably
depend upon the variation of other hemostatic components.
Although it is impractical to study how the variation of
multiple parameters influences the risk of thrombosis in
experimental systems, such studies can be done in silico.
Thus, validated simulations can generate biomedically
meaningful predictions from analysis of variation of multiple
factors, which can then can lead to hypotheses that can be
tested in vivo. The integration of coupled experimental and
validated computational models will lead to more accurate
and personalized assessments of disease risk.SUPPORTING MATERIAL
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